英文名称 |
中文名称 |
CAS号 |
操作 |
MK-1775 |
MK-1775 |
955365-80-7 |
详细
|
Ponatinib-HCl; AP24534-HCl |
普纳替尼盐酸盐;普纳替尼单盐酸盐 |
1114544-31-8 |
详细
|
CC-223 |
CC-223 |
1228013-30-6 |
详细
|
ABT-639 |
ABT-639 |
1235560-28-7 |
详细
|
GSK591; EPZ-015866 |
GSK591 (EPZ-015866) |
1616391-87-7 |
详细
|
MS023; MS-023 |
N1-甲基-N1-[[4-[4-(异丙氧基)苯基]-1H-吡咯-3-基]甲基]-1,2-乙二胺 |
1831110-54-3 |
详细
|
CHIR-090 |
CHIR 090 |
728865-23-4 |
详细
|
SH-4-54 |
SH-4-54 |
1456632-40-8 |
详细
|
EW-7197 |
EW-7197 |
1352608-82-2 |
详细
|
LY294002;LY-294002 |
LY294002/PI3K抑制剂 |
154447-36-6 |
详细
|
Lasmiditan |
拉米地坦 |
439239-90-4 |
详细
|
MK-4101 |
5-(3,3-二氟环丁基)-3-[4-[4-甲基-5-[2-(三氟甲基)苯基]-4H-1,2,4-三唑-3-基]双环[2.2.2]辛烷-1-基]-1,2,4-恶二唑 |
935273-79-3 |
详细
|
GDC-0084; GDC 0084 |
GDC-0084 |
1382979-44-3 |
详细
|
AG-221; Enasidenib |
恩西地平 |
1446502-11-9 |
详细
|
BDA-366 |
1-[[(2S)-3-(二乙基氨基)-2-羟基丙基]氨基]-4-[[(2S)-2-环氧乙烷基甲基]氨基]-9,10-蒽醌 |
1909226-00-1 |
详细
|
GNE-3511 |
化合物GNE-3511 |
1496581-76-0 |
详细
|
BP-1-102 |
4-(N-(4-环己基苄基)-2-((2,3,4,5,6-五氟-N-甲苯基)磺酰氨基)乙酰氨基)-2-羟基苯甲酸 |
1334493-07-0 |
详细
|
XMD8-87 |
5,11-二氢-2-((2-甲氧基-4-(4-甲基-1-哌嗪基)苯基)氨基)-11-甲基-6H-嘧啶并[4,5-B][1,4]苯并二氮杂卓-6-酮 |
1234480-46-6 |
详细
|
XMD16-5 |
2-((4-(4-羟基哌啶-1-基)苯基)氨基)-11-甲基-5H-苯并[E]嘧啶并[5,4-B][1,4]二氮杂卓-6(11H)-酮 |
1345098-78-3 |
详细
|
RAF-709 |
化合物RAF709 |
1628838-42-5 |
详细
|
Mivebresib; ABBV-075 |
米维布塞 |
1445993-26-9 |
详细
|
BAY-876 |
BAY-876 |
1799753-84-6 |
详细
|
SUN11602; SUN-11602 |
化合物SUN 11602 |
704869-38-5 |
详细
|
Acebilustat |
阿西鲁司特 |
943764-99-6 |
详细
|
CP-21R7 |
GSK-3Β抑制剂(CP21R7) |
125314-13-8 |
详细
|
GSK-189254A |
6-(3-CYCLOBUTYL-2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPIN-7-YLOXY)-N-METHYLNICOTINAMIDE |
720690-73-3 |
详细
|
UK-371804; Urokinase inhitibor 1 |
化合物UK371804 |
256477-09-5 |
详细
|
E 7449; E-7449 |
E7449 |
1140964-99-3 |
详细
|
NCB-0846 |
NCB-0846 |
1792999-26-8 |
详细
|
ETP-46321 |
CS-2500 |
1252594-99-2 |
详细
|
Q203 |
Q203 |
1334719-95-7 |
详细
|
STK16-IN-1 |
化合物STK16-IN-1 |
1223001-53-3 |
详细
|
MK-4827 tosylate; Niraparib tosylate |
MK-4827 tosylate; Niraparib tosylate; Niraparib对甲苯磺酸盐; MK-4827 对甲苯磺酸盐 |
1038915-73-9 |
详细
|
AMG-3969 |
AMG-3969 |
1361224-53-4 |
详细
|
GSK-2256098 |
GSK-2256098 |
1224887-10-8 |
详细
|
GSK2982772 |
GSK2982772 |
1622848-92-3 |
详细
|
CPI-637 |
(R)-4-甲基-6-(1-甲基-3-(1-甲基-1H-吡唑-4-基)-1H-吲唑-5-基)-4,5-二氢-1H-苯并[B][1,4]二氮杂-2(3H)-酮 |
1884712-47-3 |
详细
|
T0901317 |
N-(2,2,2-三氟乙基)-N-[4-[2,2,2-三氟-1-羟基-1-(三氟甲基)乙基]苯基]苯磺酰胺 |
293754-55-9 |
详细
|
NCGC00244536 |
3-(8-羟基喹啉-6-基)-N-(3-苯基丙基)苯甲酰胺 |
2003260-55-5 |
详细
|
GBT-440 |
沃塞洛托 |
1446321-46-5 |
详细
|
SRT-2104 |
玻玛西林 |
1093403-33-8 |
详细
|
Pexidartinib |
N/A |
1029044-16-3 |
详细
|
Grapiprant |
GRAPIPRANT |
415903-37-6 |
详细
|
NVS-PAK1-1 |
NVS-PAK1-1 |
1783816-74-9 |
详细
|
Icotinib hydrochloride |
Icotinib hydrochloride; 埃克替尼盐酸盐 |
1204313-51-8 |
详细
|
Lasmiditan hydrochloride |
613677-28-4 |
613677-28-4 |
详细
|
Lasmiditan hemisuccinate |
琥珀酸拉斯米迪坦 |
439239-92-6 |
详细
|
OICR-9429 |
OICR-9429 |
1801787-56-3 |
详细
|
SH5-07; SH-5-07 |
1456632-41-9 |
1456632-41-9 |
详细
|
1-methyl-3-amino-4-cyanopyrazole |
1-甲基-3-胺基-4-氰基吡唑 |
21230-50-2 |
详细
|
6-bromo-[1,2,4]triazolo[1,5-a]pyridine |
6-溴-[1,2,4]三唑并[1,5-a]吡啶 |
356560-80-0 |
详细
|
2-(2-chloro-6-morpholino-9H-purin-8-yl)propan-2-ol |
2-(2-氯-6-吗啉代-9H-嘌呤-8-基)丙-2-醇 |
1198171-62-8 |
详细
|
GSK-3326595;EPZ-015938 |
GSK-3326595 |
1616392-22-3 |
详细
|
Ticagrelor |
替卡格雷,替格雷洛,替格瑞洛 |
274693-27-5 |
详细
|
All-rac-alfa-TocopherolEP impurity C |
生育酚杂质C |
10191-41-0 |
详细
|
AZD7986 |
AZD7986 |
1802148-05-5 |
详细
|
4-bromo-2-methoxyaniline |
4-溴-2-甲氧基苯胺 |
59557-91-4 |
详细
|
3-nitro-4-((tetrahydro-2H-pyran-4-yl)MethylaMino)benzenesulfonaMide |
ABT199 中间体 |
1228779-96-1 |
详细
|
Fevipiprant |
非韦匹仑 |
872365-14-5 |
详细
|
CP-609754 (OSI754) |
CP-609754 |
1190094-64-4 |
详细
|
(6-aminopyridin-2-yl)(1-methylpiperidin-4-yl)methanone hydrogen bromide |
LASMIDITAN 中间体 |
1338000-32-0 |
详细
|
EPZ-015666;GSK3235025;GSK-3235025;EPZ-015666 |
EPZ015666 |
1616391-65-1 |
详细
|
Vipadenant; BIIB 014 |
3-(4-氨基-3-甲基苄基)-7-(呋喃-2-基)-3H-[1,2,3]三唑并[4,5-D]嘧啶-5-胺 |
442908-10-3 |
详细
|
GS-9620 |
GS9620 |
1228585-88-3 |
详细
|
Defactinib: VS-6063: PF-04554878 |
地法替尼 |
1073154-85-4 |
详细
|
Defactinib hydrochloride; VS-6063; PF-04554878 |
PF-04554878 |
1073160-26-5 |
详细
|
TAK-632; TAK-0632 |
TAK-632 |
1228591-30-7 |
详细
|
UNC1215 |
UNC1215 |
1415800-43-9 |
详细
|
BX-471; ZK-811752 |
(R)-1-(5-氯-2-(2-(4-(4-氟苄基)-2-甲基哌嗪-1-基)-2-氧代乙氧基)苯基)脲 |
217645-70-0 |
详细
|
PFI-3 |
(2E)-1-(2-羟基苯基)-3-[(1R,4R)-5-(2-吡啶基)-2,5-二氮杂双环[2.2.1]庚-2-基]-2-丙烯-1-酮 |
1819363-80-8 |
详细
|
ML324 |
ML324 |
1222800-79-4 |
详细
|
AC 55541 |
AC-55541 |
916170-19-9 |
详细
|
HTH-01-015 |
HTH-01-015 |
1613724-42-7 |
详细
|
THZ1 |
THZ1 |
1604810-83-4 |
详细
|
Liproxstatin-1 |
利普司他丁-1 |
950455-15-9 |
详细
|
SKF-86002 |
6-(4-氟苯基)-5-(4-吡啶基)-2,3-二氢咪唑并[2,1-B]-噻唑 |
72873-74-6 |
详细
|
AC-710 |
N-[4-[[[[5-(叔丁基)-3-异恶唑基]氨基]羰基]氨基]苯基]-5-[(1-乙基-2,2,6,6-四甲基-4-哌啶基)氧基]-2-吡啶甲酰胺 |
1351522-04-7 |
详细
|
Emapunil; AC-5216 |
AC-5216 |
226954-04-7 |
详细
|
SD-208 |
SD-208 |
627536-09-8 |
详细
|
RGB-286638 |
N-[1,4-二氢-3-[4-[[4-(2-甲氧基乙基)-1-哌嗪基]甲基]苯基]-4-氧代茚并[1,2-C]吡唑-5-基]-N'-4-吗啉基脲 |
784210-88-4 |
详细
|
Pilaralisib; XL147 |
2-氨基-N-[3-[N-[3-[(2-氯-5-甲氧基苯基)氨基]喹喔啉-2-基]氨基磺酰基]苯基]-2-甲基丙酰胺 |
934526-89-3 |
详细
|
SAR245408; XL-147 |
XL147 |
956958-53-5 |
详细
|
AMG-319 |
AMG319 |
1608125-21-8 |
详细
|
CEP-33779 |
N-[3-(4-甲基-1-哌嗪基)苯基]-8-[4-(甲磺酰基)苯基]-[1,2,4]三唑并[1,5-A]吡啶-2-胺 |
1257704-57-6 |
详细
|
UNC2025 |
反式-4-[2-(丁基氨基)-5-[4-[(4-甲基-1-哌嗪基)甲基]苯基]-7H-吡咯并[2,3-D]嘧啶-7-基]-环己醇 |
1429881-91-3 |
详细
|
Coelenterazine |
腔肠素 |
55779-48-1 |
详细
|
Motolimod; VTX-2337 |
MOTOLIMOD |
926927-61-9 |
详细
|
GSK-163090 |
GSK163090 |
844903-58-8 |
详细
|
CWHM-12 |
CWHM-12 |
1564286-55-0 |
详细
|
MK-8776 |
SCH-900776 |
891494-64-7 |
详细
|
Galeterone |
Galeterone |
851983-85-2 |
详细
|
MCC-950 Sodium |
MCC950 |
210826-40-7 |
详细
|
Binimetinib; MEK-162; ARRY-162;ARRY-438162 |
贝美替尼 |
606143-89-9 |
详细
|